Supernus Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $175,689 | $168,325 | $143,644 | $164,314 |
Gross Profit | 138,018 | 129,701 | 106,586 | 123,011 |
EBITDA | 65,031 | 38,922 | 16,501 | 40,665 |
EBIT | 44,929 | 18,214 | -4,248 | 18,989 |
Net Income | 38,497 | 19,916 | 124 | 1,175 |
Net Change In Cash | 175,689 | 168,325 | 143,644 | 164,314 |
Free Cash Flow | 53,320 | 35,560 | 38,153 | 44,994 |
Cash | 31,673 | 52,089 | 63,401 | 75,054 |
Basic Shares | 56,016 | 55,724 | 55,626 | 55,301 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $607,521 | $667,238 | $579,775 | $520,397 |
Gross Profit | 523,742 | 580,017 | 504,714 | 467,938 |
EBITDA | 90,043 | 153,443 | 129,187 | 212,404 |
EBIT | 5,184 | 67,813 | 96,598 | 192,402 |
Net Income | 1,316 | 60,711 | 53,424 | 126,950 |
Net Change In Cash | 607,521 | 667,238 | 579,775 | 520,397 |
Cost of Revenue | -110,314 | -85,206 | 107,259 | |
Free Cash Flow | 110,534 | 116,414 | 125,082 | 134,950 |
Cash | 75,054 | 93,120 | 203,434 | 288,640 |
Basic Shares | 55,506 | 61,679 | 54,356 | 53,689 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.69 |
2024-06-30 | $0.36 |
2024-03-31 | $0.26 |
2023-12-31 | $0.89 |
